MGMT and central nervous system cancer: There is ongoing discussion about the best method to assess MGMT dowregulation in gliomas for its use as predictive biomarker of response to alkylating agent therapy, including promoter methylation analysis, levels of mRNA or protein expression, or enzyme activity [4].